CONICET | Buscador de Institutos y Recursos Humanos

Alzheimer´s disease (AD) is a neurodegenerative disease characterized by cognitive, memory and other mental impairments. There is no cure and it is usually terminal; the worldwide prevalence is 16.94 million. The etiology is multifactorial and poorly understood. Many hypotheses have been proposed; the most accepted are related to a deficiency of acetylcholine (ACh), the formation of senile plaques of β-amyloid (Aβ) protein outside the cells and the formation of intracellular neurofibrillary of hyperphosphorylated TAU protein (p-TAU) [1].Tacrine (TAC) is an inhibitor of the enzyme acetylcholinesterase. TAC was approved by FDA for the treatment of the symptoms of AD, however, it was later reported to cause hepatotoxicity and adverse pharmacological effects [2]. On the other hand, carbamazepine (CBZ) is an antiepileptic drug on the current market, it was shown to potentiate lysosomal autophagy by reducing levels of Aβ and p-TAU and improving memory in mice models of AD [2].Dendrimers are three-dimensional polymers with unique properties to the field of drug delivery systems (DDS). G4 and G4,5 PAMAM dendrimers (positive and negative charge, respectively) are optimal as DDS because drug molecules can be loaded by encapsulation, noncovalent interactions or covalent binding to the surface functional groups [3]. The complexed drugs obtain the DDS physicochemical properties, increasing their solubility in aqueous media significantly; they also alter their pharmacokinetics and biodistribution, improving brain arrival [4]. Therefore, the aim of this study was to obtain and characterize complexes between dendrimers and drugs.So far, the complexes were obtained with both drugs and characterized by light scattering and zeta potential. Further, infrared spectroscopy (FTIR) was performed to determine the interactions between drugs and dendrimers, and in vitro drug release was studied using the micro-dialysis method.

enviar mensaje